Современные возможности химиотерапии трижды негативного рака молочной железы (обзор литературы)

1. Божок А.А., Семиглазов В.Ф., Семиглазов В.В. Факторы прогноза при раке молочной железы. Соврем. онкология. 2005; 7 (1): 4.
2. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М.: ФГУ «МНИОИ им. П.А.Герцена» Минздравсоцразвития России, 2012.
3. Blichert-Toft M, Rose C, Andersen JA et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst. Monogr 1992; р. 19–25.
4. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568–81.
5. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009; 18: 125–32.
6. Поддубная И.В., Карселадзе А.И., Кулевич Е.Е. Морфология тройного негативного рака молочной железы. Архив патологии. 2010; 72 (2): 8–12.
7. Поддубная И.В. Клиническая характеристика тройного негативного рака молочной железы. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2010; 22 (1): 71–6.
8. Lin NU, Vanderplas A, Hughes ME et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2009; 27 (Abstr 543).
9. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–67.
10. Манзюк Л.В., Артамонова Е.В. Таксотер в химиотерапии рака молочной железы. Независимое издание для практикующих врачей. Онкология. 2006; 24: 12–6.
11. Химиотерапия при метастатическом раке молочной железы. Маммология. Хирургия молочной железы. http://mammalogy.eurodoctor.ru/chemotherapybreastcancer
12. Частота встречаемости рака молочной железы. http://www.panaceya. com.ua/med/ article/view/92a460d6cb845 eedb2214cd8 b296c859
13. Семиглазов В.Ф., Дашян Г.А., Семиглазов В.В. и др. Лечение «трижды негативного» рака молочной железы. Фарматека. 2009; 18: 14–7.
14. Стенина М., Фролова М., Скрыпникова М. Базальноподобный (тройной негативный) рак молочной железы: молекулярные особенности, течение и возможные терапевтические подходы. Врач. 2010; 3: 24–8.
15. Voduc KD, Cheang MC, Tyldesley S et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684–91.
16. Carey L, Dees E, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329–34.
17. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275–81.
18. Rouzier R, Perou C, Symmans W et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678–85.
19. Hayes D, Thor A, Dressler L et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496–506.
20. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16 (8): 2672–85.
21. Rocca A, Paradiso A, Sismondi P et al. Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1031.
22. Седаков И.Е. Химиотерапия рака молочной железы. Новости медицины и фармации. Маммология. 2009. http://www.mif-ua.com/archive/article/10749
23. Cheang MCU, Voduc D, Tu D et al. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1032.
24. Ellis G, Green S, Russell C et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel vs weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel vs neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 12.
25. Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62: 667–72.
26. Alvarado Miranda A, Lara Medina FU, Arce C et al. Phase II open, single-arm trial: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple-negative breast cancer. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1135.
27. Alba E, Chacon JI, Lluch A et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1015.
28. Pivot X, Li R, Thomas S et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesteron receptor-human epidermal growth factor receptor-2-negative breast cancer. Eur J Cancer 2009; 45: 2940–6.
29. Greil R, Moik M, Reitsamer R et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009; 35 (10): 1048–54.
30. Gerber B, Eidtmann H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis analysis of the GeparQuinto study (GBG 44). ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Abstr 1006.
31. Gonzalez-Angulo AM, Green MC, Murray JL et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1016.
32. Sparano J, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663–71.
33. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741. Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431–9.
34. Garber J, Richardson A, Harris L et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Presented at the 29th San Antonio Breast Cancer Symposium; December 14–17. 2006; San Antonio, Texas. Poster 3074.
35. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008; 115: 359–63.
36. Mehta RS, Liu C. Clinical outcome of triple-negative breast cancer with BRCA mutation in the context of dose-dense and or metronomic chemotherapy. ASCO Annual Meet June 3–7, Chicago, IL, 2011: Post 1109.
37. Gluz O, Nitz UA, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 2008; 19: 861–70.
38. Yi S, Uhm J, Cho E et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy [abstr 1008]. Proc Am Soc. Clin Oncol 2008; 26: 15.
39. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210–7.
40. Hortobagyi GN, Perez E, Vdoljak E et al. Analysis of overall survival amongpatienys with metastatic breast cancer receiving either ixabepilone plus capecitabine or capecitabine alone and review of results from two randomized phase III trials. ASCO Breast 2008.
41. Rugo HS, Thomas ES, Lee RK et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2007; 106 (Suppl. 1): S270. Abstr 6069.
42. Farmer H, McCabe N, Lord C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–21.
43. O’Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADP-ribose)polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial [abstr 3]. Proc Am Soc Clin Oncol 2009; 27: 18.
44. Cotter MB, Pierce A, McGowan PM et al. PARP1 in triplenegative breast cancer: Expression and therapeutic potential. ASCO Annual Meet June 3–7, Chicago, IL, 2011: Post 1061.
45. Liu J, Fleming GF, Tolaney SM et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triplenegative breast cancer. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 5028.
46. Siziopikou K, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 1: 104–7.
47. Carey L, Rugo H, Marcom P et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [abstr 1009]. J Clin Oncol 2008; 26: 15.
48. O’Shaughnessy J, Weckstein D, Vukelja S et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstr 308]. Breast Cancer Res Treat 2007; 106: 32.
49. Corkery B, Crown J, Clynes M et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20 (5): 862–7.
50. Mullooly M, McGowan PM, Sukor SU et al. ADAMs as new therapeutic targets for triple-negative breast cancer. ASCO Annual Meet, June 3–7, Chicago, IL, 2011: Post 1062.
51. Malin D, Chen Feng, Schiller C et al. Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer. Clin Cancer Res 2011; 17 (15): 5005–15.
52. Reis Filho JS, Tutt ANJ. Triple negative tumors: a critical review. Histopathology 2008; 52: 108–18.
53. Finn R, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/«triple-negative» breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319–26.
54. Finn RS, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059 [abstr]. San Antonio Breast Cancer Symposium December 12, San Antonio, Texas, 2008. Abstr a3118.
55. Carey L, Winer E, Viale G et al. Triple-negative Breast Cancer: Disease Entity or Title of Convenience? Nat Rev Clin Oncol 2010; 7 (12): 683–92.
56. O’Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of Avastin in combination with chemotherapy in patients with HER2-negative metastatic breast cancer [poster 207]. SABCS, Dec 2009.
57. Brufsky A, Valero V, Tiangco B et al. Impact of bevacizuma (BEV) on efficacy of second-line chemotherapy (CT) for triplenegative breast cancer (TNBC): Analysis of RIBBON-2. ASCO Annual Meet, June 3–7, Chicago, IL, 2011. Abstr 1010.
58. Mayer EL, Scheulen ME, Beckman J et al. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. ASCO Annual Meet June 3–7, Chicago, IL, 2011: Post 1092.
59. Mayer IA, Burris H, Bendel J et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, December 9–13, 2009, San Antonio, Texas, USA.

М.А.Секундова1, 2, А.М.Сдвижков1, 2, В.И.Борисов1

1 ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г. Москвы;
2 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России

________________________________________________

M.A.Sekundova, A.M.Zdvizhkov, V.I.Borisov